Ganglioside Intake Increases Plasma Ganglioside Content in Human Participants.

Area of Science:

• Gastroenterology
• Immunology
• Nutritional Science

Background:

• Preclinical studies link intestinal ganglioside levels to inflammatory bowel disease (IBD).
• Low ganglioside levels correlate with increased pro-inflammatory signals in the gut.
• Determining the safety and bioavailability of dietary gangliosides is crucial for potential therapeutic use in IBD.

Purpose of the Study:

• To assess the safety and bioavailability of dietary ganglioside consumption.
• To evaluate the impact of ganglioside supplementation on plasma ganglioside levels and intestinal permeability in healthy volunteers.
• To explore the effects of ganglioside supplementation on quality of life in patients with IBD.

Main Methods:

• An 8-week supplementation study in 18 healthy volunteers (HVs) and a small pilot study in 5 IBD patients.
• HVs received either a milk fat fraction with 43 mg/d ganglioside or a placebo.
• Analyses included plasma ganglioside characterization (LC-QQQ MS), intestinal permeability (lactulose/mannitol test), and quality of life questionnaires.

Main Results:

• No adverse events were reported with dietary ganglioside intake.
• Ganglioside consumption significantly increased plasma total GD3 levels by 35% in HVs (P < .05).
• HVs showed a 19% reduction in intestinal permeability (P = .04), and IBD patients reported improved emotional health (39%, P < .01) and systemic symptoms (36%, P < .02).

Conclusions:

• Dietary gangliosides are safe and bioavailable, potentially improving intestinal integrity.
• Ganglioside supplementation may enhance quality of life for IBD patients.
• Gangliosides show promise for treating IBD and other disorders involving altered ganglioside metabolism.